Thursday, January 24, 2013
Europe's Innovative Medicines Initiative has launched seven new public-private partnerships with
a total budget of €237 million ($313 million). In contrast to many of the
organization's disease-focused projects, three of the new consortia are taking
a drug-centric approach that includes plans to optimize small molecule binding
kinetics and develop new delivery systems for RNA- and protein-based
Cain, C. SciBX 6(3); doi:10.1038/scibx.2013.51 Published online Jan.
AND INSTITUTIONS MENTIONED
AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K.
(Xetra:BAYN), Leverkusen, Germany
European Federation of Pharmaceutical Industries and
Innovative Medicines Initiative, Brussels, Belgium
(Euronext:SAN; NYSE:SNY), Paris, France